作为潜在的抗阿尔茨海默氏症剂的新型 styryl-thiazole 杂交物
Niki Gouleni1, Annalisa Di Rienzo2, Ahmet Yılmaz3
1Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens Athens Greece.
RSC medicinal chemistry
|November 29, 2023
概括
新型 styryl-thiazole 杂交物被开发用于阿尔茨海默病 (AD) 治疗. 化合物6i表现出显著的神经保护作用,抑制了乙胆酶 (AChE),并阻止了粉样β (Aβ) 聚合,显示出AD治疗的前景.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药物发现 药物发现 药物发现
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是粉样β (Aβ) 斑块和团.
- 多目标导向带 (MTDLs) 战略为开发针对AD等复杂疾病的新疗法提供了一个有希望的方法.
- 开发有效的AD治疗方法需要解决其多因素性质.
研究的目的:
- 设计,合成和评估新型士-醇混合物作为阿尔茨海默病 (AD) 潜在的多目标药物.
- 为了识别具有神经保护性,乙胆酶 (AChE) 抑制性和抗胺基因性质的化合物.
- 通过体外和体研究来评估合成化合物的AD治疗潜力.
主要方法:
- styryl-thiazole杂交物 (化合物6a-p) 的合理设计和合成.
- 在Aβ1-42暴露的人类神经母细胞瘤细胞中评估神经保护作用.
- 在体外酶抑制试验和分子对接研究以评估ACHE抑制活性.
- 对抗Aβ1-42聚合的抗氨基原性质的评估.
- 在物理化学性质的形预测.
主要成果:
- 化合物6e和6i表现出显著的神经保护作用,增加了Aβ1-42暴露细胞中的细胞活力.
- 6e和6i都表现出强大的ACHE抑制特性.
- 与6e相比,化合物6i对Aβ1-42聚合表现出更高的活性 (预防率超过80%).
- 在分析表明,化合物6i具有有利的物理化学特性,这表明更好的药物相似性.
结论:
- 化合物6i已成为阿尔茨海默氏症 (AD) 治疗的非常有前途的多重向药物.
- styryl-thiazole支架在开发AD的新型MTDL方面是有效的.
- 进一步的体内研究是有必要的,以阐明AD模型中化合物6i的详细作用机制.
相关概念视频
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
128
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
128
Antihypertensive Drugs: Thiazide-Class Diuretics
680
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
680
Antidepressant Drugs: MAOIs and Other Agents
248
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
248
Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276


